Abstract
DNA in eukaryotic cells is packaged into chromatin. The main packaging component of chromatin is the nucleosome, and this is composed of proteins known as histones. Histones can be reversibly modified in several ways, and the best characterized of these modifications is histone acetylation. This is a reversible modification, which is carried out by two families of enzymes, the histone acetyltransferases (HATs), and the histone deacetylases (HDACs). These enzymes have important activities in many cellular processes including transcription, DNA replication and cell cycle progression. The mechanisms underlying tumor formation are multifaceted, and often involve mutations or alterations of genes involved with the regulation and control of the cell cycle or cell death. Because of their important roles in the regulation of such events, enzymes that affect histone acetylation status are increasingly being associated with tumors. This article describes some of the current knowledge about histone acetyltransferases and histone deacetylases, and how their multitudinal roles in cellular events may have important roles in tumorigensis.
Keywords: Histone Acetylation/, histone acetyltransferases, GNAT (GCN5-related N-acetyltransferase), TUMORIGENESIS, Oncogenes, Tumor Suppressor Genes, DNA Repairing Genes, Methylation, CELLULAR PROCESSES, Retinoblastoma Protein
Current Molecular Medicine
Title: Histone Acetylation / Deacetylation and Cancer: An “Open” and “Shut” Case?
Volume: 1 Issue: 4
Author(s): S. G. Gray and B. T. Teh
Affiliation:
Keywords: Histone Acetylation/, histone acetyltransferases, GNAT (GCN5-related N-acetyltransferase), TUMORIGENESIS, Oncogenes, Tumor Suppressor Genes, DNA Repairing Genes, Methylation, CELLULAR PROCESSES, Retinoblastoma Protein
Abstract: DNA in eukaryotic cells is packaged into chromatin. The main packaging component of chromatin is the nucleosome, and this is composed of proteins known as histones. Histones can be reversibly modified in several ways, and the best characterized of these modifications is histone acetylation. This is a reversible modification, which is carried out by two families of enzymes, the histone acetyltransferases (HATs), and the histone deacetylases (HDACs). These enzymes have important activities in many cellular processes including transcription, DNA replication and cell cycle progression. The mechanisms underlying tumor formation are multifaceted, and often involve mutations or alterations of genes involved with the regulation and control of the cell cycle or cell death. Because of their important roles in the regulation of such events, enzymes that affect histone acetylation status are increasingly being associated with tumors. This article describes some of the current knowledge about histone acetyltransferases and histone deacetylases, and how their multitudinal roles in cellular events may have important roles in tumorigensis.
Export Options
About this article
Cite this article as:
Gray G. S. and Teh T. B., Histone Acetylation / Deacetylation and Cancer: An “Open” and “Shut” Case?, Current Molecular Medicine 2001; 1 (4) . https://dx.doi.org/10.2174/1566524013363537
DOI https://dx.doi.org/10.2174/1566524013363537 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetic and Epigenetic Heterogeneity in Cancer: The Ultimate Challenge for Drug Therapy
Current Drug Targets Renaissance of the Biologically Active Vitamin A Derivatives: Established and Novel Directed Therapies for Cancer and Chemoprevention
Current Pharmaceutical Design Selectively Replicating Adenoviruses for Oncolytic Therapy
Current Cancer Drug Targets Discovery of BRM Targeted Therapies: Novel Reactivation of an Anticancer Gene
Letters in Drug Design & Discovery Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications
Current Drug Targets Resveratrol as an Enhancer of Apoptosis in Cancer: A Mechanistic Review
Anti-Cancer Agents in Medicinal Chemistry FOXO Transcription Factors and their Role in Disorders of the Female Reproductive Tract
Current Drug Targets RING Finger E3 Ubiquitin Ligases: Structure and Drug Discovery
Current Pharmaceutical Design MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets Recent Progress in Research on Ribosome Inactivating Proteins
Current Protein & Peptide Science Regeneration of Pancreatic β-Cells in vivo as a Potential Therapeutic Approach for Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Role of Histone Acetylation in Cell Cycle Regulation
Current Topics in Medicinal Chemistry Modulation of Sirtuins: New Targets for Antiageing
Recent Patents on CNS Drug Discovery (Discontinued) Curcumin Targets in Inflammation and Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Cinnamic Acid Derivatives as Anticancer Agents-A Review
Current Medicinal Chemistry Protein-Protein Interactions: Lessons Learned
Current Medicinal Chemistry - Anti-Cancer Agents Receptor Tyrosine Kinases as Therapeutic Targets in Malignant Glioma
Reviews on Recent Clinical Trials Heat Shock Proteins as Prognostic Markers of Cancer
Current Cancer Drug Targets HPV-mediated Cervical Cancer: A Systematic Review on Immunological Basis, Molecular Biology, and Immune Evasion Mechanisms
Current Drug Targets MicroRNAs in the Pathobiology of Multiple Myeloma
Current Cancer Drug Targets